2020. Safety of Long-Term Proactive Management with Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients with Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial. SKIN The Journal of Cutaneous Medicine. 4, 5 (Sep. 2020), s31. DOI:https://doi.org/10.25251/skin.4.supp.31.